Prostate Enucleation With Intravesical Botox Injections in Treating BPH and Bladder Overactivity (BPH Botox)
BPH, Intravesical Botox, ThuLEP
About this trial
This is an interventional treatment trial for BPH focused on measuring Intravesical Botox, ThuLEP, BPH, Overactive Bladder, Bladder Outlet Obstruction
Eligibility Criteria
Inclusion Criteria: Males age > 40 Patients diagnosed with Benign Prostatic Hyperplasia (BPH) and referred for ThuLEP surgery Lower urinary tract symptoms (LUTS) of Overactive Bladder Syndrome (OABS) frequency - urgency - urge incontinence episodes - dysuria - nocturia and eligible for bladder botox injections International Prostate Symptom Score (IPSS) ≥ 17 Overactive Bladder Symptom Score (OABSS) ≥ 7 Participants have failed, are intolerant, or bad candidates for anticholinergic medication treatment for OAB Exclusion Criteria: History of bladder/prostate cancer History of pelvic radiotherapy History of neurological diseases Presence of active Urinary Tract Infection (UTI) Previous Bladder Outlet Procedure (Transurethral resection of prostate (TURP) Transurethral Incision of Prostate (TUIP) - UroLift, etc..) History of adverse reaction to Botox injections Post-void residual (PVR) greater than 300 ml History of clean intermittent catheterization Patients unable to stop anticoagulation of antiplatelet inhibitors 3 days prior to procedure
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Patients receiving ThuLEP surgery only
Patients receiving ThuLEP surgery + Intravesical Botox Injections
50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. No Botox injections will be given.
50 patients diagnosed with benign prostatic hyperplasia and overactive bladder and referred for ThuLEP to treat their urinary symptoms. Botox injections will be given during the surgery.